JPRN-UMIN000024552
Completed
Phase 4
Investigation of satisfaction, efficacy and safety after switching from daily GLP-1 receptor agonist to weekly dulaglutide in patients with type 2 diabetes -open label, randomized, parallel group controlled clinical study- - Study for satisfaction and efficacy of dulaglutide
ConditionsType 2 diabetes
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Type 2 diabetes
- Sponsor
- Hokkaido University Graduate School
- Enrollment
- 32
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Patients who were taking weekly GLP\-1 receptor agonist at the time of obtaining informed consent 2\)Patients who have experienced severe diabetic ketosis, diabetic coma, or past history of pre\-coma within six months 3\)Patients with pregnancy or lactation 4\)Patients who are taking systemic corticosteroid 5\)Type 1 diabetes 6\)Patients with severe infection, pre or post operation and severe trauma 7\)Patients with severe liver dysfunction 8\)Patients with severe renal dysfunction 9\)Patients who are deemed to be unsuitable by the investigator
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Comparison of the efficacy of botulinum toxin and triamcinolone in patients with hypertrophic scars treated with PDL laserIRCT20220121053776N1Iran University of Medical Sciences12
Recruiting
Phase 3
Evaluation of the effect of fractional carbon dioxide laser with platelet-rich plasma in the treatment of burn scarsBurn scar.Scar conditions and fibrosis of skinL90.5IRCT20210515051307N2Skin and Stem cellResearch Center of Tehran University20
Not yet recruiting
Phase 1
Comparison of the efficacy of Stromal Vascular Fraction injection and ow level laser in the treatment of alopeciaIRCT20200127046282N16Shahid Beheshti University of Medical Sciences30
Recruiting
Phase 3
Comparison of oral N-acetil cystein Vs oral Pentoxyphilline in patients with Lichen planopillarisIRCT20210208050292N1Iran University of Medical Sciences30
Active, not recruiting
Phase 1
Subject reported outcomes on satisfaction, efficacy and safety with Luxerm® in the field-directed treatment of thin or non-hyperkeratotic and non-pigmented Actinic Keratosis of the face or the scalpThin or non-hyperkeratotic and non-pigmented Actinic Keratosis on the face and scalpMedDRA version: 19.1Level: HLTClassification code 10020648Term: HyperkeratosesSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2017-000066-29-DEGalderma R&D50